146 related articles for article (PubMed ID: 35738917)
1. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C; Kulbe H; Dreher F; Taube ET; Chekerov R; Horst D; Hummel M; Kessler T; Pietzner K; Kassuhn W; Heitz F; Muallem MZ; Lang SM; Vergote I; Dorigo O; Lammert H; du Bois A; Angelotti T; Fotopoulou C; Sehouli J; Braicu EI
Gynecol Oncol; 2022 Aug; 166(2):334-343. PubMed ID: 35738917
[TBL] [Abstract][Full Text] [Related]
2. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.
Tucker SL; Gharpure K; Herbrich SM; Unruh AK; Nick AM; Crane EK; Coleman RL; Guenthoer J; Dalton HJ; Wu SY; Rupaimoole R; Lopez-Berestein G; Ozpolat B; Ivan C; Hu W; Baggerly KA; Sood AK
Clin Cancer Res; 2014 Jun; 20(12):3280-8. PubMed ID: 24756370
[TBL] [Abstract][Full Text] [Related]
3. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
[TBL] [Abstract][Full Text] [Related]
4. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
5. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: A nationwide study.
De Decker K; Wenzel HHB; Bart J; van der Aa MA; Kruitwagen RFPM; Nijman HW; Kruse AJ
Acta Obstet Gynecol Scand; 2023 Mar; 102(3):246-256. PubMed ID: 36734363
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
Hyman DM; Long KC; Tanner EJ; Grisham RN; Arnold AG; Bhatia J; Phillips MF; Spriggs DR; Soslow RA; Kauff ND; Levine DA
Gynecol Oncol; 2012 Aug; 126(2):224-8. PubMed ID: 22579790
[TBL] [Abstract][Full Text] [Related]
8. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
[TBL] [Abstract][Full Text] [Related]
9. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
10. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.
Kleinmanns K; Fosse V; Davidson B; de Jalón EG; Tenstad O; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102783. PubMed ID: 32454402
[TBL] [Abstract][Full Text] [Related]
11. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma.
Kojima N; Yoshida H; Kuno I; Uehara T; Uno M; Ishikawa M; Kato T
Cancer Med; 2019 Aug; 8(10):4598-4604. PubMed ID: 31243928
[TBL] [Abstract][Full Text] [Related]
13. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
14. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
15. Diffusion-Weighted Magnetic Resonance Imaging and Morphological Characteristics Evaluation for Outcome Prediction of Primary Debulking Surgery for Advanced High-Grade Serous Ovarian Carcinoma.
Li H; Lu J; Deng L; Guo Q; Lin Z; Zhao S; Ge H; Qiang J; Gu Y; Liu Z
J Magn Reson Imaging; 2023 May; 57(5):1340-1349. PubMed ID: 36054024
[TBL] [Abstract][Full Text] [Related]
16. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
17. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
18. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
19. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
Auer K; Bachmayr-Heyda A; Aust S; Grunt TW; Pils D
Cancer Lett; 2017 Mar; 388():158-166. PubMed ID: 27940126
[TBL] [Abstract][Full Text] [Related]
20. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Javellana M; Hoppenot C; Lengyel E
Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
